why choose us

First received: August 02, 2022

Clinical Trial: Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Kidney Cancer

Study Type: INTERVENTIONAL


Official Title: A Pilot Study of the Immunomodulatory Agent Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)

Brief Summary: The purpose of this study is to determine the safety and tolerability of acarbose in combination of immunotherapy based standard of care therapy in advanced renal cell carcinoma patients.

Read more